Trabectedin + Pazopanib + Ipilimumab + Nivolumab for Soft Tissue Sarcoma

This trial tests a combination of four treatments—Ipilimumab, Nivolumab, Pazopanib, and Trabectedin—to determine if adding Pazopanib is safe and effective for individuals with soft tissue sarcoma, a cancer affecting connective tissues. Researchers aim to discover if this combination can help when the cancer is difficult to treat or has returned. Individuals with a confirmed diagnosis of relapsed or hard-to-treat soft tissue sarcoma who have already tried other treatments might be suitable for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this new combination therapy.

The trial requires that you stop taking other anti-cancer agents and investigational drugs before participating. If you are on growth factors, you must stop them at least 7 days before starting the trial. The protocol does not specify about other medications, so it's best to discuss with the study team.

Earlier research showed that the combination of ipilimumab and nivolumab holds promise for certain types of sarcoma, with manageable side effects similar to other available treatments. Studies also indicate that nivolumab, when combined with chemotherapy, is generally well-tolerated by patients with soft tissue sarcoma.

Pazopanib, another drug in this trial, proved effective in treating advanced soft tissue sarcoma in past studies. The most common side effects included tiredness, changes in liver test results, and diarrhea. Importantly, these studies reported no severe side effects.

Trabectedin has been tested in patients with advanced soft tissue sarcoma and helped control the disease. Its safety profile aligns with previous findings, showing it is generally well-tolerated.

Researchers are excited about the combination of Trabectedin, Pazopanib, Ipilimumab, and Nivolumab for soft tissue sarcoma because it brings together a unique mix of mechanisms. Unlike existing treatments that primarily focus on surgery, radiation, and chemotherapy, this combination includes immunotherapy agents, Ipilimumab and Nivolumab, which help the body's immune system target cancer cells more effectively. Trabectedin works by interfering with the cancer cell’s DNA, while Pazopanib is a tyrosine kinase inhibitor that can block tumor growth by targeting specific proteins. This multi-faceted approach offers the potential for a more comprehensive attack on the cancer, which is why researchers are hopeful about its effectiveness.

This trial will evaluate the combination of four drugs—ipilimumab, nivolumab, trabectedin, and pazopanib—for treating advanced soft tissue sarcoma. Research has shown that combining ipilimumab, nivolumab, and trabectedin may control tumors and improve survival rates more effectively than using nivolumab alone. Additionally, studies have found that nivolumab and ipilimumab together can delay disease progression more effectively than pazopanib. These findings suggest that this combination might be more effective for certain types of sarcoma.⁶⁷⁸⁹¹⁰